IGF-1 LR3
Insulin-like Growth Factor 1 Long R3
Overview
IGF-1 LR3 is a modified version of IGF-1 with 83 amino acids (vs. 70 in native IGF-1) and an arginine substitution at position 3. These modifications dramatically reduce binding to IGF binding proteins, extending its half-life from minutes to approximately 20-30 hours and increasing its bioavailability and potency.
Mechanism of Action
IGF-1 LR3 binds to the IGF-1 receptor with similar affinity to native IGF-1 but with dramatically lower affinity for IGF binding proteins, keeping it active in circulation much longer. It promotes muscle cell hyperplasia (new cell formation), protein synthesis, glucose uptake, and inhibits protein degradation. It also has significant anti-catabolic and fat-oxidizing properties.
Dosage Information
Typical Dose
20-50 mcg
Frequency
Once daily
Administration
Subcutaneous or intramuscular injection
Notes
Can be injected SubQ for systemic effects or IM bilaterally into trained muscles post-workout. Typically cycled 4-6 weeks on, 4 weeks off. Monitor blood glucose levels as hypoglycemia can occur. Do not combine with insulin.
Potential Side Effects
Research References
Community Experiences
No experiences shared yet. Be the first!
Stacking Compatibility
Quick Facts
- Administration
- Subcutaneous or intramuscular injection
- Typical Dose
- 20-50 mcg
- Frequency
- Once daily
- References
- 2 studies